Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 2/20 | 0.44 |
| ▸ | ALOX5AP | P20292 | 17/20 | 0.41 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.39 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9966546 | 0.89 | IDO1 (0.46) | IDO1ALOX5APHDAC3NCOR2 | |
| SCHEMBL9966447 | 0.88 | ALOX5AP (0.41) | IDO1ALOX5AP | |
| SCHEMBL14315778 | 0.85 | ALOX5AP (0.44) | IDO1ALOX5AP | |
| SCHEMBL9966451 | 0.83 | OTUD7B (0.43) | IDO1ALOX5AP | |
| SCHEMBL9966343 | 0.81 | ALOX5AP (0.44) | IDO1ALOX5AP | |
| SCHEMBL14313992 | 0.80 | ALOX5AP (0.41) | IDO1ALOX5AP | |
| SCHEMBL14315771 | 0.80 | MAP4K4 (0.50) | IDO1HDAC3NCOR2 | |
| SCHEMBL9966342 | 0.80 | ALOX5AP (0.56) | ALOX5AP | |
| SCHEMBL14313998 | 0.78 | ALOX5AP (0.45) | ALOX5AP | |
| SCHEMBL9966488 | 0.77 | MAP4K4 (0.44) | IDO1ALOX5APHDAC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120322795-A1 | BIARYLAMIDE INHIBITORS OF LEUKOTRIENE PRODUCTION | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-12-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120322795-A1 | BIARYLAMIDE INHIBITORS OF LEUKOTRIENE PRODUCTION | LTB4R, LTB4R2, LTC4S | IDO1 819/4885ALOX5AP 43/4885HDAC3 1912/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.